Alberto Quesada - Establishment Labs Vice President Quality & OUS Regulatory Affairs
ESTA Stock | USD 48.47 0.07 0.14% |
President
Mr. Alberto Quesada is Vice President, Quality OUS Regulatory Affairs of the Company. From May 2010 to December 2016, Mr. Quesada was a Quality Director and Management Representative at Boston Scientific in Costa Rica, where he was a Quality Director at the companys site in Heredia from May 2010 to June 2016, and then a Management Representative at the companys site in Coyol from July 2016 to December 2016. Prior to that, Mr. Quesada was with Allergan Corporation from November 2000 to May 2010, where he served in senior quality management roles. He also previously held roles at Baxter Healthcare Corporationrationration, Kativo Chemical Industries and GTE Sylvania since 2017.
Age | 51 |
Tenure | 7 years |
Professional Marks | MBA |
Address | Building B15 and 25, Alajuela, Costa Rica |
Phone | 506 2434 2400 |
Web | https://www.establishmentlabs.com |
Establishment Labs Management Efficiency
The company has return on total asset (ROA) of (0.1694) % which means that it has lost $0.1694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.3775) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of April 27, 2024, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.29. At present, Establishment Labs' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.9 M, whereas Total Assets are forecasted to decline to about 150.6 M.Similar Executives
Showing other executives | PRESIDENT Age | ||
Kimberley Elting | Orthofix Medical | 59 | |
Stanley Peters | CONMED | 45 | |
Tyler Lipschultz | Orthofix Medical | 57 | |
Terence Berge | CONMED | 54 | |
Heather Cohen | CONMED | 51 | |
Peter Shagory | CONMED | 55 | |
Stanley III | CONMED | 49 | |
Jon Serbousek | Orthofix Medical | 63 | |
Robert Goodwin | Orthofix Medical | 46 | |
Todd Garner | CONMED | 55 | |
David Murray | CONMED | 76 | |
D Lee | Artivion | 56 | |
Patrick Beyer | CONMED | 58 | |
Mark Snyder | CONMED | 61 | |
Nathan Folkert | CONMED | 43 | |
Davide Bianchi | Orthofix Medical | 52 | |
John Kennedy | CONMED | 66 | |
Daniel Jonas | CONMED | 56 | |
James Cunniff | Electromed | 58 | |
Johonna Pelletier | CONMED | 51 | |
Wilfredo RuizCaban | CONMED | 53 |
Management Performance
Return On Equity | -15.38 | ||||
Return On Asset | -0.17 |
Establishment Labs Leadership Team
Elected by the shareholders, the Establishment Labs' board of directors comprises two types of representatives: Establishment Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Establishment. The board's role is to monitor Establishment Labs' management team and ensure that shareholders' interests are well served. Establishment Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Establishment Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Hung, Independent Director | ||
Lisa Gersh, Independent Director | ||
Juan Quiros, CEO, Director | ||
Heather Brennan, Head Operations | ||
Nicholas Lewin, Independent Director | ||
Roberto Mezerville, Chief Officer | ||
Lisa Colleran, Independent Director | ||
Paul Rodio, Chief Officer | ||
Renee Gaeta, CFO | ||
Dennis Condon, Independent Director | ||
Salvador Santos, COO | ||
Jeremy Livianu, General Counsel | ||
Alberto Quesada, Vice President Quality & OUS Regulatory Affairs | ||
Edward Schutter, Independent Director | ||
Allan Weinstein, Independent Director | ||
Ivan Bilic, Senior OUS | ||
Eddie Oliveira, Vice President of Sales, Brazil | ||
Ross Mansbach, General Officer | ||
Jeffrey Bettinger, Global People | ||
Neeta Toprani, Corporate Secretary | ||
Rosalyn dIncelli, Medical Clinical | ||
Rajbir Denhoy, Chief Officer | ||
Salvador Dada, Chief Officer | ||
Elizabeth Newman, VP Unit |
Establishment Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Establishment Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -15.38 | ||||
Return On Asset | -0.17 | ||||
Profit Margin | (0.48) % | ||||
Operating Margin | (0.70) % | ||||
Current Valuation | 1.47 B | ||||
Shares Outstanding | 27.46 M | ||||
Shares Owned By Insiders | 11.44 % | ||||
Shares Owned By Institutions | 78.08 % | ||||
Number Of Shares Shorted | 4.89 M | ||||
Price To Earning | (20.11) X |
Pair Trading with Establishment Labs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Establishment Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Establishment Labs will appreciate offsetting losses from the drop in the long position's value.Moving against Establishment Stock
0.8 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
0.69 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
0.53 | IDXX | IDEXX Laboratories Financial Report 7th of May 2024 | PairCorr |
0.46 | CTSO | Cytosorbents Crp Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Establishment Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Establishment Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Establishment Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Establishment Labs Holdings to buy it.
The correlation of Establishment Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Establishment Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Establishment Labs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Establishment Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Establishment Labs Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Establishment Stock analysis
When running Establishment Labs' price analysis, check to measure Establishment Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Establishment Labs is operating at the current time. Most of Establishment Labs' value examination focuses on studying past and present price action to predict the probability of Establishment Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Establishment Labs' price. Additionally, you may evaluate how the addition of Establishment Labs to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Establishment Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. If investors know Establishment will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Establishment Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.07) | Revenue Per Share 6.451 | Quarterly Revenue Growth (0.28) | Return On Assets (0.17) | Return On Equity (15.38) |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Establishment Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Establishment Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Establishment Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.